Clinical Trial Update: Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma [Phase 1, Phase 2]

View source ↗

Summary

This document reports an update on a Phase 1/2 trial evaluating a telomerase peptide vaccine in combination with temozolomide for advanced malignant melanoma. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• GV1001 Telomerase peptide vaccine (GV1001)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Oslo University Hospital | Conditions: Malignant Melanoma | Phase 1, Phase 2 | Status: COMPLETED